NDA 019614 · Azurity
Verelan
Verapamil Hydrochloride · Oral
Last checked: Nov 20, 2026Latest source record: Oct 1, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1990
May 29, 1990
Approved uses
1
Original approval plus efficacy supplements
Registered trials
143
16 Phase 3, 13 recruiting
FAERS reports
4,312
3,916 serious, 958 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 27, 2024.
INDICATIONS AND USAGE Verapamil hydrochloride sustained-release capsules are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide...
Mechanism: Mechanism of Action Essential Hypertension Verapamil HCl exerts antihypertensive effects by decreasing systemic vascular resistance, usually without orthostatic decreases in blood pressure or reflex tachycardia; bradycardia (rate less than 50 beats/minute is uncommon). Verapamil HCl regularly reduces arterial pressure at rest and at a given level of exercise by dilating peripheral arterioles and reducing the total peripheral resistance (afterload) against which the heart works.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 29, 1990 Original approval · Type 3 - New Dosage Form
4 products under this application
- VERELAN · VERAPAMIL HYDROCHLORIDE 120MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB
- VERELAN · VERAPAMIL HYDROCHLORIDE 360MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription
- VERELAN · VERAPAMIL HYDROCHLORIDE 240MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB
- VERELAN · VERAPAMIL HYDROCHLORIDE 180MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Verapamil" as an intervention, any sponsor and status, largest first.
- INVEST: INternational VErapamil SR Trandolapril STudyPivotal-lookingCompleted
University of FloridaAcademic, hospital or other
NCT00133692 · 22,000 participants · Start Sep 1997
Drug: Verapamil SR/Trandolapril/Hydrochlorothiazide (HCTZ); Atenolol/HCTZ/Trandolapril · For: Hypertension; Coronary Artery Disease
Sites: Gainesville, Florida
- Coronavirus (COVID-19) ACEi/ARB InvestigationPivotal-lookingSuspended
National University of Ireland, Galway, IrelandAcademic, hospital or other
NCT04330300 · 2,414 participants (planned) · Start Apr 30, 2020 · Primary completion Jul 31, 2021
Drug: Thiazide or Thiazide-like diuretics; Calcium Channel Blockers and 2 more · For: Hypertension; COVID-19
Sites: Galway, Ireland
- Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation TrialPivotal-lookingCompleted
Mayo ClinicAcademic, hospital or other
NCT00911508 · 2,204 participants · Start Nov 13, 2009 · Primary completion Dec 31, 2017
Drug: Rate or Rhythm Control Therapy · For: Atrial Fibrillation; Arrhythmia
Sites: Little Rock, Arkansas; Los Angeles, California; Sacramento, California · 118 sites in all
AbbottIndustry
NCT00233532 · 2,000 participants · Start Mar 2004 · Primary completion Jun 2005
Drug: Trandolapril · For: Hypertension
- A Study for Prevention of Kidney Disease in Diabetic Patients (BENEDICT)Pivotal-lookingCompleted
AbbottIndustry
NCT00235014 · 1,204 participants · Start Mar 1997 · Primary completion Jan 2006
Drug: trandolapril; trandolapril/verapamil and 2 more · For: Hypertension; Diabetes
- Dual Antithrombotic Therapy With Dabigatran and Ticagrelor in Patients With ACS and Non-valvular AF Undergoing PCIPivotal-lookingRecruiting
Medical University of GdanskAcademic, hospital or other
NCT04695106 · 1,194 participants (planned) · Start Oct 25, 2021 · Primary completion Jul 11, 2026
Drug: Ticagrelor; Dabigatran Etexilate and 2 more · For: Atrial Fibrillation; Antithrombotic Therapy; Acute Coronary Syndrome and 1 more
Sites: Gdansk, Poland
- Flecainide Safety in Patients With Coronary Artery Disease and Atrial FibrillationPivotal-lookingRecruiting
Universitaire Ziekenhuizen KU LeuvenAcademic, hospital or other
NCT07405671 · 988 participants (planned) · Start Sep 2026 · Primary completion Dec 2029
Drug: flecainide; Sotalol or Amiodarone · For: Atrial Fibrillation (AF); Coronary Artery Disease
Sites: Aalst, Belgium; Bonheiden, Belgium; Bruges, Belgium · 14 sites in all
- Amiodarone or Verapamil in COVID-19 Hospitalized Patients With SymptomsPivotal-lookingCompleted
Nicolaus Copernicus UniversityAcademic, hospital or other
NCT04351763 · 804 participants · Start May 20, 2020 · Primary completion May 25, 2021
Drug: Amiodarone; Verapamil · For: COVID-19
Sites: Bydgoszcz, Poland
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dyspnoea357
- nausea353
- drug interaction316
- dizziness293
- hypotension287
- fatigue277
- diarrhoea271
- abdominal pain245
- vomiting244
- cough242
- headache238
- fall237
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 82 |
| 2005 | 130 |
| 2006 | 122 |
| 2007 | 58 |
| 2008 | 90 |
| 2009 | 53 |
| 2010 | 86 |
| 2011 | 79 |
| 2012 | 112 |
| 2013 | 61 |
| 2014 | 109 |
| 2015 | 160 |
| 2016 | 187 |
| 2017 | 187 |
| 2018 | 199 |
| 2019 | 217 |
| 2020 | 243 |
| 2021 | 273 |
| 2022 | 488 |
| 2023 | 407 |
| 2024 | 438 |
| 2025 | 331 |
| 2026 | 200 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Additive antianginal effect of verapamil in patients receiving propranolol.
Bassan M, Weiler-Ravell D, Shalev O · Br Med J (Clin Res Ed) 1982 · Clinical Trial, Randomized Controlled Trial
- Beta-Blocker (Bisoprolol) vs Calcium-Channel Blocker (Verapamil) in Nonobstructive Hypertrophic Cardiomyopathy: A Randomized Triple-Crossover Physiologic Trial.
Bjerregaard L, Dybro AM, Saaby L, et al. · J Am Coll Cardiol 2026 · Randomized Controlled Trial, Comparative Study
- Oral verapamil with chemotherapy for advanced non-small cell lung cancer: a randomised study.
Millward MJ, Cantwell BM, Munro NC, et al. · Br J Cancer 1993 · Clinical Trial, Randomized Controlled Trial
- Role of P-glycoprotein inhibitors in children with drug-resistant epilepsy.
Elkhayat HA, Aly RH, Elagouza IA, et al. · Acta Neurol Scand 2017 · Randomized Controlled Trial
- Sustained-release verapamil formulations for treating hypertension.
Frishman WH, Lazar EJ · J Clin Pharmacol 1992 · Clinical Trial
- Greater occipital nerve injection with methylprednisolone as transitional therapy in episodic cluster headache: Results from an RCT.
Brandt RB, Mulleners WM, Couturier E, et al. · Cephalalgia 2025 · Clinical Trial, Phase IV, Multicenter Study
Sponsor: Azurity
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.